Valproic acid
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Valproic Acid/Sodium Valproate (Depakote) |
| FDA Approval | Yes (for epilepsy) |
| Used for | Investigational use in glioblastoma for its HDAC inhibition properties |
| Clinical Trial Phase | Retrospective studies and a prospective phase II trial |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Liver enzyme non-induction, potential increase in chemotherapy concentration, somnolence, constipation, potential liver toxicity |
| OS without | Median survival with enzyme-inducing anticonvulsants: 11 months |
| OS with | Valproic acid users: retrospective study shows median survival of 16.9 months, prospective study shows 29.6 months |
| PFS without | Not specified |
| PFS with | Prospective study shows median PFS of 10.5 months |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: Valproic acid, an anti-epileptic drug and HDAC inhibitor, has shown potential to improve clinical outcomes in glioblastoma patients. While initial retrospective analyses suggest benefits, particularly in extending median survival and PFS, the results are contested. The debate continues, emphasizing the need for rigorously designed clinical trials to conclusively determine Valproic acid's efficacy in glioblastoma treatment.
From Ben Williams Book: Not specified
Loading comments...
